A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH)

Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH)

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Jul 2017

At a glance

  • Drugs Namodenoson (Primary)
  • Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Can-Fite BioPharma
  • Most Recent Events

    • 17 Jul 2017 According to Can-Fite BioPharma media release, Hadassah Medical Center and Rabin Medical Center serve as clinical sites for the trial.
    • 05 Jun 2017 According to Can-Fite BioPharma media release, Hadassah is one of the clinical sites where Can-Fite has received Institutional Review Board (IRB) approval to conduct this trial.
    • 05 Jun 2017 According to Can-Fite BioPharma media release, initiation of patient enrollment is expected during the third quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top